Sector
PharmaceuticalsOpen
₹6,686.4Prev. Close
₹6,683.85Turnover(Lac.)
₹15,952.77Day's High
₹6,699.05Day's Low
₹6,64752 Week's High
₹7,107.4552 Week's Low
₹5,205.55Book Value
₹1,543.55Face Value
₹5Mkt Cap (₹ Cr.)
1,11,147.02P/E
27.07EPS
246.89Divi. Yield
0.6Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.
Dr. Reddy's Laboratories Ltd stock has gained a total of 21% in the last one year, and almost 17% gain since the beginning of the year.
Here are some of the stocks that may see significant price movement today: UltraTech Cement, ICICI Bank, Punjab National Bank, etc.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | -15.7 | -43.6 | -76.9 | -113.5 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 24,256.5 | 20,517.8 | 18,413.1 | 17,097.2 |
Net Worth | 24,240.8 | 20,474.2 | 18,336.2 | 16,983.7 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 14,405.2 | 13,349.1 | 11,850.4 | 9,359.3 |
yoy growth (%) | 7.91 | 12.64 | 26.61 | -3.7 |
Raw materials | -5,045.9 | -4,123 | -3,573.8 | -2,631 |
As % of sales | 35.02 | 30.88 | 30.15 | 28.11 |
Employee costs | -2,434.6 | -2,270.1 | -2,030.2 | -1,843 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 2,223.8 | 3,056.2 | 2,775.8 | 696.99 |
Depreciation | -814.3 | -835 | -789.2 | -774.1 |
Tax paid | -600.6 | -869.8 | 161.9 | -130.1 |
Working capital | 1,395.8 | 1,078.3 | 508.8 | -170.1 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 7.91 | 12.64 | 26.61 | -3.7 |
Op profit growth | -17.3 | 9.31 | 115.77 | -23.81 |
EBIT growth | -27.1 | 9.89 | 271.62 | -52.56 |
Net profit growth | -25.75 | -25.57 | 418.2 | -59.04 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 27,916.4 | 24,587.9 | 21,439.1 | 18,972.2 | 17,460 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 27,916.4 | 24,587.9 | 21,439.1 | 18,972.2 | 17,460 |
Other Operating Income | 94.7 | 81.8 | 106.1 | 75.3 | 57 |
Other Income | 909 | 1,092.5 | 554.7 | 339.4 | 676.7 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,853.75 | 160.77 | 4,47,463.98 | 237.82 | 0.72 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,498.65 | 87.61 | 1,45,516.6 | 430 | 0.55 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,659.7 | 33.69 | 1,33,820.75 | 1,055.94 | 0.78 | 3,752.25 | 346.4 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,451.7 | 77.91 | 1,17,090.09 | 469 | 0.81 | 2,394 | 201.77 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,118.55 | 25.8 | 1,12,713.3 | 1,700.8 | 0.27 | 4,035.4 | 156.19 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Co-Chairman & Managing Directo
G V Prasad
Executive Chairman
K Satish Reddy
Independent Director
Shikha Sanjaya Sharma
Lead Independent Director
Leo Puri
Independent Director
K P Krishnan
Independent Director
Pennv Wan
Company Sec. & Compli. Officer
K Randhir Singh
Independent Director
Arun M. Kumar
Independent Director
Claudio Albrecht
Independent Director
Sanjiv Mehta
Independent Director
Alpna Seth
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Dr Reddys Laboratories Ltd
Summary
Dr Reddys Laboratories Ltd (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddys offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. The companys major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddys operates in markets across the globe. Its major markets include - USA, India, Russia & CIS countries, and Europe.Dr Reddys Laboratories was incorporated in the year 1984 in Hyderabad. The company was established by Dr Anji Reddy with an initial capital outlay of Rs 25 lakh. The company made their beginning with the manufacture of Active Pharmaceutical Ingredients and Intermediates (API) and commenced operations with a single drug in a 60-tonne facility near Hyderabad, India. In the year 1986, the company shares were listed on the Bombay Stock Exchange. Also, they entered international market with exports of Methyldopa.In the year 1987, the company obtained first USFDA approval for Ibuprofen API. In the year 1988, they acquired Benzex Laboratories Pvt Ltd to expand their Bulk Actives business. In the year 1990, they exported Norfloxacin and Ciprofloxacin to Europe
Read More
The Dr Reddys Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹6660.7 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dr Reddys Laboratories Ltd is ₹111147.02 Cr. as of 13 Sep ‘24
The PE and PB ratios of Dr Reddys Laboratories Ltd is 27.07 and 4.58 as of 13 Sep ‘24
The 52-week high/low is the highest and lowest price at which a Dr Reddys Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Dr Reddys Laboratories Ltd is ₹5205.55 and ₹7107.45 as of 13 Sep ‘24
Dr Reddys Laboratories Ltd's CAGR for 5 Years at 19.29%, 3 Years at 10.67%, 1 Year at 17.80%, 6 Month at 6.06%, 3 Month at 10.29% and 1 Month at -2.94%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice